Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older

Clinical Infectious Diseases

Volumn 64, Issue 6, 2017, Pages 785-793

  Izurieta, Hector S ^a,e   Wernecke, Michael ^b   Kelman, Jeffrey ^c   Wong, Sarah ^b   Forshee, Richard ^a   Pratt, Douglas ^a   Lu, Yun ^a   Sun, Qin ^b   Jankosky, Christopher ^a   Krause, Philip ^a   Worrall, Chris ^c   MaCurdy, Tom ^b   Harpaz, Rafael ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Acumen LLC   (United States)

^c CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

elderly; Herpes Zoster vaccine; opthalmic zoster; post herpetic neuralgia; vaccine effectiveness

Indexed keywords

PNEUMOCOCCUS VACCINE; VARICELLA ZOSTER VACCINE; LIVE VACCINE;

AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; GERIATRICS; GROUPS BY AGE; HEALTH CARE UTILIZATION; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEDICARE; OUTCOME ASSESSMENT; POSTHERPETIC NEURALGIA; PREDICTIVE VALUE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY ANALYSIS; VACCINATION; COMORBIDITY; ETHNOLOGY; FOLLOW UP; IMMUNOLOGY; UNITED STATES; VARICELLA ZOSTER VIRUS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MEDICARE; OUTCOME ASSESSMENT (HEALTH CARE); UNITED STATES; VACCINATION; VACCINES, ATTENUATED;

EID: 85035121073     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw854     Document Type: Article

References (34)

1. Oxman MN, Levin MJ, Johnson GR, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271–84.
2. Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013; 13:170.
3. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4:e004833.
4. Tyring SK. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 2007; 57(6 Suppl):S136–42.
5. Kost RG, Straus SE. Postherpetic neuralgia–pathogenesis, treatment, and prevention. N Engl J Med 1996; 335:32–42.
6. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19(23–24):3076–90.
7. Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol 2011; 174:1054–61.
8. Merck & Co., ZOSTAVAX (Zoster vaccine live): important information regarding storage and handling [package insert]. Available at: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi.pdf. Accessed October 1.
9. Marin M, Yawn BP, Hales CM, et al. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother 2015; 11:1157–64.
10. Tseng HF, Lewin B, Hales CM, et al. Zoster vaccine and the risk of postherpetic neuralgia in patients who developed herpes zoster despite having received the zoster vaccine. J Infect Dis 2015; 212:1222–31.
11. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160–6.
12. Morrison VA, Johnson GR, Schmader KE, et al.; Shingles Prevention Study Group. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60:900–9.
13. Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis 2014; 59:913–9.
14. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013; 10:e1001420.
15. Jackson LA, Reynolds MA, Harpaz R. Hospitalizations to treat herpes zoster in older adults: causes and validated rates. Clin Infect Dis 2008; 47:754–9.
16. Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc 2011; 86:1146–53.
17. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011; 52: 332–40.
18. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308:43–9.
19. Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 2000; 95:573–85.
20. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 2010; 21:383–8.
21. Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? JAMA 2013; 309:241–2.
22. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006; 35:337–44.
23. Zaadstra BM, Chorus AM, van Buuren S, Kalsbeek H, van Noort JM. Selective association of multiple sclerosis with infectious mononucleosis. Mult Scler 2008; 14:307–13.m
24. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics 2005; 61:962–73.
25. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004; 23:2937–60.
26. Schmader KE, Levin MJ, Gnann JW, Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 2012; 54:922–8.
27. Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis 2016; 213:1872–5.
28. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997–2002. Epidemiol Infect 2005; 133: 245–53.
29. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis 2005; 191: 2002–7.
30. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605–9.
31. Soni A, SC Hill. Average Annual Health Care Use and Expenses for Shingles among the U.S. Civilian Noninstitutionalized Population, 2003–2005 Washington, DC: Agency for Healthcare Research and Quality, 2007.
32. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3:335–42.
33. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27: 882–7.
34. Hales CM, Harpaz R, Bialek SR. Self-reported herpes zoster, pain, and health care seeking in the Health and Retirement Study: implications for interpretation of health care-based studies. Ann Epidemiol 2016; 26:441–446.e3.